
Alexander N Shoushtari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6255084/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nature Biotechnology, 2022, 40, 499-506.	9.4	110
2	Refractive Shifts and Changes in Corneal Curvature Associated With Antibody–Drug Conjugates. Cornea, 2022, 41, 792-801.	0.9	6
3	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
4	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	13.5	223
5	Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). Journal of Clinical Oncology, 2022, 40, 1059-1067.	0.8	26
6	Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?. Cancer Discovery, 2022, 12, 599-601.	7.7	6
7	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. British Journal of Dermatology, 2022, 187, 401-410.	1.4	21
8	Specific human endogenous retroviruses predict metastatic potential in uveal melanoma. JCI Insight, 2022, 7, .	2.3	5
9	Combination intravitreous melphalan and bevacizumb for cutaneous metastatic melanoma to the vitreous and retina. American Journal of Ophthalmology Case Reports, 2022, 26, 101519.	0.4	1
10	Risk of nonâ€ e cral cutaneous melanoma after the diagnosis of acral melanoma. British Journal of Dermatology, 2022, , .	1.4	0
11	Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. Cancers, 2022, 14, 2638.	1.7	12
12	Urethral Melanoma – Clinical, Pathological and Molecular Characteristics. Bladder Cancer, 2022, 8, 291-301.	0.2	1
13	Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy. JAMA Oncology, 2022, 8, 1352.	3.4	8
14	Are our patients doing better? A single institution experience of an evolving management paradigm for sinonasal mucosal melanoma. Oral Oncology, 2021, 112, 105006.	0.8	12
15	Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma. Clinical Cancer Research, 2021, 27, 1476-1490.	3.2	29
16	The association between tumor mutational burden and prognosis is dependent on treatment context. Nature Genetics, 2021, 53, 11-15.	9.4	139
17	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nature Communications, 2021, 12, 729.	5.8	212
18	Monitoring vulvar melanoma response to combined immunotherapy and radiotherapy with <i>in vivo</i> reflectance confocal microscopy. JDDG - Journal of the German Society of Dermatology, 2021, 19, 768-770.	0.4	2

#	Article	IF	CITATIONS
19	Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma. Journal of Clinical Oncology, 2021, 39, 867-869.	0.8	4
20	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy. Clinical Cancer Research, 2021, 27, 5993-6000.	3.2	70
21	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 2021, 13, .	5.8	54
22	Loss of polycomb repressive complex 1 activity and chromosomal instability drive uveal melanoma progression. Nature Communications, 2021, 12, 5402.	5.8	34
23	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. New England Journal of Medicine, 2021, 385, 1196-1206.	13.9	376
24	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. Clinical Cancer Research, 2021, 27, 2226-2235.	3.2	25
25	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. Cancer Discovery, 2021, 11, 1212-1227.	7.7	139
26	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. , 2021, 9, e003395.		7
27	Metastatic melanoma concurrent to the urinary bladder and endometrium: Case report. Journal of Medical Imaging and Radiation Oncology, 2021, , .	0.9	1
28	546â€Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM). , 2021, 9, A576-A576.		3
29	538â€Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp. , 2021, 9, A568-A568.		2
30	Isolated Abducens Nerve Palsy Following Pembrolizumab. Neuro-Ophthalmology, 2020, 44, 182-185.	0.4	15
31	DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy. Journal of Neuro-Oncology, 2020, 146, 339-346.	1.4	17
32	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Annals of Surgical Oncology, 2020, 27, 1180-1188.	0.7	39
33	Quality of Life Concerns in Patients with Uveal Melanoma after Initial Diagnosis. Ocular Oncology and Pathology, 2020, 6, 184-195.	0.5	4
34	Primary tumor volume as a predictor of distant metastases and survival in patients with sinonasal mucosal melanoma. Head and Neck, 2020, 42, 3316-3325.	0.9	3
35	Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clinical Cancer Research, 2020, 26, 5869-5878.	3.2	131
36	Training Oncologists in the Time of COVID â€19. Oncologist, 2020, 25, 546-547.	1.9	5

#	Article	IF	CITATIONS
37	PD-1 Blockade in Chinese versus Western Patients with Melanoma. Clinical Cancer Research, 2020, 26, 4171-4173.	3.2	13
38	Leveraging Systematic Functional Analysis to Benchmark an <i>In Silico</i> Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. Cancer Research, 2020, 80, 4233-4243.	0.4	18
39	Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. , 2020, 8, e000331.		66
40	Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma. Modern Pathology, 2020, 33, 2244-2255.	2.9	23
41	Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. Oncologist, 2020, 25, 140-149.	1.9	38
42	Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. Journal of Clinical Oncology, 2020, 38, 1655-1663.	0.8	138
43	A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational New Drugs, 2019, 37, 282-290.	1.2	32
44	MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors. Neuro-Oncology, 2019, 21, 1578-1586.	0.6	42
45	About Face: Molecular Aberrations in Head and Neck Mucosal Melanomas. Clinical Cancer Research, 2019, 25, 3473-3475.	3.2	1
46	Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. Oncologist, 2019, 24, e196-e197.	1.9	31
47	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	9.4	2,702
48	Hepatic abnormalities identified by staging MRI and accuracy of MRI of patients with uveal melanoma. British Journal of Ophthalmology, 2019, 103, 1266-1271.	2.1	8
49	Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1â€based therapy. Cancer, 2019, 125, 884-891.	2.0	43
50	GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Reports, 2018, 22, 2455-2468.	2.9	75
51	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. JAMA Oncology, 2018, 4, 98.	3.4	125
52	Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). Journal of Clinical Oncology, 2018, 36, 1232-1239.	0.8	207
53	Rates of <i>ERBB2</i> Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an <i>ERBB2</i> -Amplified Acral Melanoma. Clinical Cancer Research, 2018, 24, 5815-5819.	3.2	25
54	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of Clinical Oncology, 2017, 35, 226-235.	0.8	458

#	Article	IF	CITATIONS
55	Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive Care in Cancer, 2017, 25, 2155-2167.	1.0	14
56	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	15.2	2,473
57	Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. Melanoma Research, 2017, 27, 57-64.	0.6	39
58	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical Cancer Research, 2017, 23, 2972-2980.	3.2	106
59	Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. Journal of the National Cancer Institute, 2017, 109, djw260.	3.0	56
60	Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy. Ophthalmology, 2017, 124, 1788-1798.	2.5	95
61	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	1,266
62	<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-15.	1.5	275
63	A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. Melanoma Research, 2016, 26, 272-277.	0.6	31
64	Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head and Neck, 2016, 38, 1310-1317.	0.9	65
65	Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. Gynecologic Oncology Reports, 2016, 16, 42-46.	0.3	40
66	Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nature Genetics, 2016, 48, 675-680.	9.4	236
67	The efficacy of antiâ€PDâ€l agents in acral and mucosal melanoma. Cancer, 2016, 122, 3354-3362.	2.0	236
68	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. Oncologist, 2016, 21, 848-854.	1.9	154
69	Treatment of Uveal Melanoma. Cancer Treatment and Research, 2016, 167, 281-293.	0.2	18
70	Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. , 2015, 3, 22.		95
71	Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer. , 2015, 3, .		12
72	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human Pathology, 2015, 46, 357-365.	1.1	252

#	Article	IF	CITATIONS
73	Novel Treatment Targets in Sarcoma: More Than Just the GIST. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e488-e495.	1.8	7
74	GNAQ and GNA11 mutations in uveal melanoma. Melanoma Research, 2014, 24, 525-534.	0.6	99